Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0000950170-25-053257
Filing Date
2025-04-11
Accepted
2025-04-11 16:10:09
Documents
13
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A ubx-20241231.htm   iXBRL 10-K/A 910219
2 EX-31.1 ubx-ex31_1.htm EX-31.1 9687
3 EX-31.2 ubx-ex31_2.htm EX-31.2 9696
  Complete submission text file 0000950170-25-053257.txt   1189883

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ubx-20241231.xsd EX-101.SCH 53425
15 EXTRACTED XBRL INSTANCE DOCUMENT ubx-20241231_htm.xml XML 11162
Mailing Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 416-1192
Unity Biotechnology, Inc. (Filer) CIK: 0001463361 (see all company filings)

EIN.: 264726035 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-38470 | Film No.: 25832180
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)